Renaparin®
Kidney Transplantation
Key Facts
About Corline Biomedical
Corline Biomedical, founded in 2005 and based in Uppsala, Sweden, has developed the Corline Heparin Conjugate (CHC™), a unique macromolecular technology that mimics the natural blood-compatible lining of blood vessels. The company operates a dual business model, generating revenue by supplying its CHS™ coating to medical device partners while advancing its proprietary pipeline, Renaparin® and Cytoparin™, in high-value regenerative medicine fields like kidney transplantation and cell therapy. Listed on Nasdaq First North (CORLINE), Corline leverages a strong scientific foundation of over 100 publications to drive innovation and partnerships in areas of significant unmet clinical need.
View full company profileAbout Corline Biomedical
Corline Biomedical, founded in 2005 and based in Uppsala, Sweden, has developed the Corline Heparin Conjugate (CHC™), a unique macromolecular technology that mimics the natural blood-compatible lining of blood vessels. The company operates a dual business model, generating revenue by supplying its CHS™ coating to medical device partners while advancing its proprietary pipeline, Renaparin® and Cytoparin™, in high-value regenerative medicine fields like kidney transplantation and cell therapy. Listed on Nasdaq First North (CORLINE), Corline leverages a strong scientific foundation of over 100 publications to drive innovation and partnerships in areas of significant unmet clinical need.
View full company profileTherapeutic Areas
Other Kidney Transplantation Drugs
| Drug | Company | Phase |
|---|---|---|
| TCD601 for Kidney Tolerance | ITB Med | Phase 2 |
| TCD601 for Kidney Induction | ITB Med | Phase 2 |